Abstract
What has the cell-kill paradigm and its dominance of cancer research, diagnosis, treatment, and outcome assessment achieved in the context of the “War on Cancer” since the enactment of the National Cancer Act of 1971? The answer will vary depending on how achievement is measured and who does the assessment. For example, in a 1996 review article titled The war on cancer [505] marking the 25th birthday of the National Cancer Act of 1971, the author used a quote from Charles Dickens to dramatize its failure: “Dead, your Majesty. Dead, my lords and gentlemen. Dead, right reverends and wrong reverends of every order. Dead, men and women, born with Heavenly compassion in your hearts. And dying thus around us every day”. Less than a year later, an editorial written by a former Director of the NCI rejoiced “Happy birthday ‘War’, you deserve a pat on the back” [506]. Both authors converged on crediting major scientific advances made during this period, especially the breathtaking advances in molecular biology and molecular genetics, including the genome project, that have revolutionized our knowledge about cancer. Yet, while both see a brighter future after these advances are applied to the practice of medicine, the former author concluded, “We must develop new approaches to control this plague of deaths, adopting an ethic of prevention ….to prevent disease before it becomes invasive and metastatic” [507].
Insanity: doing the same thing over and over again and expecting different results.
– Albert Einstein
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Notes
- 1.
Drugs targeting rare diseases.
References
Sporn MB. The war on cancer. Lancet 1996;347:1377–1381.
DeVita VT. The War on cancer has a birthday, and a present. J Clin Oncol 1997;15:867–869.
Sporn MB. Op. cit.
Jemal A, Ward E, Thun M () Declining Death Rates Reflect Progress against Cancer. PLoS ONE 2010;5:e9584. doi:10.1371/journal.pone.0009584
Kantarjian H. The Price of Drugs for Chronic Myeloid Leukemia (CML); A Reflection of the Unsustainable Prices of Cancer Drugs: From the Perspective of a Large Group of CML Experts. Blood 2013;121:4439–4442.
Bach PB. Limits on Medicare’s Ability to Control Rising Spending on Cancer Drugs. N Engl J Med 2009;360:626–633.
Kantarjian H. Op. cit.
Bailar JC, Gornik HL. Cancer undefeated. N Engl J Med 1997;336:1569–1574.
Faguet GB. The War on Cancer. Op. cit.
World Oncology Forum: Are we winning the war on cancer? Web 1 June 2013. http://www.eso.net/varie/wof.html
Cavalli F. An appeal to world leders. Lancet 2013;381:425–426.
STOP CANCER NOW! On this World Cancer Day 2013, participants of the World Oncology Forum raise the alarm about the increasing devastation caused by cancer across the world. Web 1 Jun 2013. www.eso.net/images/Allegati/statementenglish.pdf
Sustaining progress against cancer in an era of cost containment: Discussion Paper. Kean M, Lessor T. (Eds). Cambriidge, MA: Feinstein Kean Healthcare; June 2012. Web 16 Jul. 2013. http://turningthetideagainstcancer.org/sustaining-progress-discussion-paper.pdf
SEER Cancer statistics: Breast, Table 4:11 Op. cit.
Special Report: Measurement of Progress Against Cancer. Extramural Committee to Assess Measures of Progress Against Cancer. J Natl Cancer Inst 1990;82:825–835.
Wu J, Josepj SO, Muggia FM. Targeted Therapy: Its Status and Promise in Selected Solid Tumors, Part I. Oncology 2012;26:1–12.
Cancer Statistics 2013: A prsentation from the American Cancer Society. Web 3 Sept. 2013. http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2013/cancer-statistics-2013-slide-presentation.pdf
Cancer Facts & Fcer igures: American Cancer Society. Web 20 Jan. 2013. http://www.cancer.org/acs/groups/content/@nho/documents/document/2008cafffinalsecuredpdf.pdf
Cancer Trends, Progress Report: 2011/2012. Web 20 Jan. 2013. http://progressreport.cancer.gov/highlights.asp
Andersen LD, Remington P, Trentham-Dietz A, et al. Assessing a decade of progress in cancer control. The Oncologist 2002;7:200–204.
Kuenstner S, Langelotz C, Budach V, et al. The comparability of quality of life scores. a multitrait multimethod analysis of the EORTC QLQ-C30, SF-36 and FLIC questionnaires. Eur J Cancer 2002;38:339–48.
Slevin ML, Stubbs L, Plant HJ, et al. Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public. BMJ 1990;300:1458–1460.
Kiebert G, Wait S, Beernhard J, et al. Practice and Policy of measuring quality of life and health economics in cancer trials: A survey among co-operative trial groups. Qual Life Res 2000;9:1073–1080.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Faguet, G. (2015). The Cell-Kill Paradigm: Bleak Outcomes. In: The Conquest of Cancer. Springer, Dordrecht. https://doi.org/10.1007/978-94-017-9165-6_9
Download citation
DOI: https://doi.org/10.1007/978-94-017-9165-6_9
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-017-9164-9
Online ISBN: 978-94-017-9165-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)